Oxycodone Depot Teva (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodone Depot Teva, is an opioid analgesic presented as a depot formulation for systemic use. It is indicated for the management of moderate to severe chronic pain in adult patients when around‑the‑clock treatment is required. GNH USA supplies Oxycodone Depot Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodone Depot Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone Depot Teva is an opioid analgesic used in the management of pain pathways that involve central nociceptive processing. - Chronic cancer pain: provides long‑acting relief for patients with persistent tumor‑related pain. - Post‑surgical pain: maintains analgesia during the postoperative recovery period when oral dosing is not feasible. - Severe non‑cancer chronic pain: offers continuous opioid coverage for conditions such as severe osteoarthritis or neuropathic pain unresponsive to other therapies.

Oxycodone Depot Teva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: sensation of queasiness, sometimes progressing to vomiting. - Drowsiness: mild sedation or feeling of fatigue. - Dry mouth: decreased salivary flow causing oral discomfort. - Dizziness: light‑headed sensation, especially when standing quickly. - Pruritus: mild itching without rash.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Opioid use disorder: dependence or addiction with misuse potential. - Adrenal insufficiency: impaired cortisol production leading to fatigue and weakness. - Severe allergic reaction: anaphylaxis with rash, swelling, and airway compromise. - QT interval prolongation: cardiac rhythm disturbance detectable on ECG.

When prescribing Oxycodone Depot Teva, clinicians should consider several safety measures to minimize risk. - Assess pain severity and opioid tolerance: ensure the patient requires long‑acting opioid therapy. - Evaluate respiratory function: monitor for signs of depression, especially in opioid‑naïve individuals. - Review concomitant medications: avoid combining with other central nervous system depressants. - Counsel on dependence risk: discuss safe use, storage, and disposal. - Monitor for endocrine effects: watch for signs of adrenal insufficiency or hormonal changes. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Oxycodone Depot Teva can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use markedly increases risk of respiratory depression and profound sedation. - CNS depressants: concurrent administration with alcohol, barbiturates or other sedatives can cause life‑threatening respiratory compromise. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise oxy‑dosed plasma levels, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can reduce conversion to active metabolites, affecting analgesia. - Anticholinergics: may exacerbate constipation and urinary retention. - Diuretics: can increase risk of orthostatic hypotension when combined with opioid‑induced vasodilation.